Colorectal Neuroendocrine Tumor G1 C3272611
A rare tumor type arising from neuroendocrine cells in the colon or rectum. It can affect adults and may present with various symptoms depending on hormone production. Treatment depends on tumor size, grade, and spread.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Chronic diarrhea
(gastrointestinal)Generalized symptoms
(oncologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Facial flushing
(integumentary)Abdominal pain
(gastrointestinal)Wheezing
(respiratory)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Endoscopic resection
Endoscopic mucosal or submucosal resection for localized G1 neuroendocrine tumors meeting size criteria, offering curative intent with minimal morbidity.
Active surveillance protocol
Careful monitoring strategy for small, incidental G1 tumors without high-risk features, with intervention reserved for evidence of progression.
Additional treatment options
Surgical resection
Partial colectomy or more extensive surgical resection for larger tumors, those with concerning features, or unsuccessful endoscopic removal.
surgicalSomatostatin analog therapy
Octreotide or lanreotide administration for symptom control and potential tumor growth inhibition in advanced or metastatic disease.
medicationSymptom management and nutrition
Dietary modifications to manage potential carcinoid syndrome symptoms including trigger avoidance and small frequent meals.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Colorectal Neuroendocrine Tumor G1 C3272611?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Benson AB, Ajani JA, Catalano PJ, et al. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors, Version 2.2024. J Natl Compr Canc Netw. 2024;22(4):213-228.
Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2022;23(1):e28-e42.
Kaderli RM, Spanjol M, Kollár A, et al. Therapeutic Options for Appendiceal and Colorectal Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2019;26(8):2599-2610.
Cives M, Strosberg JR. Neuroendocric Tumors: A Review. N Engl J Med. 2020;382(10):937-950.
Medication Comparisons
Compare medications used to treat Colorectal Neuroendocrine Tumor G1 C3272611. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy